Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 296, Issue 2, 2001, Pages 388-395

  Yu, Rosie Z ^a   Zhang, Hong ^a   Geary, Richard S ^a   Graham, Mark ^a   Masarjian, Lilit ^a   Lemonidis, Kristina ^a   Crooke, Rosanne ^a   Dean, Nicholas M ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FAS ANTIGEN; ISIS 13866; ISIS 22023; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TARGETING; DRUG UPTAKE; FEMALE; GENE TARGETING; GENE THERAPY; KUPFFER CELL; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM; TRANSCRIPTION REGULATION;

ALGORITHMS; ANIMALS; ANTIGENS, CD95; FEMALE; HALF-LIFE; HEPATOCYTES; LIVER; MICE; MICE, INBRED BALB C; NUCLEASE PROTECTION ASSAYS; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER;

EID: 0035142861     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pharmacokinetics of antisense oligonucleotides
2. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice
3. Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal transduction inhibitors
4. 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells
5. Pharmacology of antisense therapeutic agents - Cancer and inflammation
6. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats
7. In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development
8. Comparison of four basic models of indirect pharmacodynamic responses
9. Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302)
10. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration
11. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion
12. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice
13. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type i in the adult male rat following single injections and continuous infusion
14. The hepatic perisinusoidal stellate cell
15. Prediction of furan pharmacokinetics from hepatocyte studies: Comparison of bioactive and hepatic dosimetry in rats, mice, and humans
16. Quantitation of phosphorothioate oligonucleotides in human plasma
17. Characterization of a potent and specific class of antisense oligonucleotide inhibitors of human protein kinase C-α expression
18. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides
19. Lethel effect of the anti-fas antibody in mice
20. Phase I clinical/ pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
21. Identification and partial purification of human double strand RNase activity: A novel terminating mechanism for oligoribonucleotide antisense drugs
22. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis
23. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects